SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 10/21/2017 1:29:49 PM - Followers: 43 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the beginning of phase 2 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in the 4th quarter of 2017. A CML combination drug safety study for BP1001 is also expected to be completed by late 2017. Patent protection for their neutral lipid delivery system has been allowed.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional funds  the company has 6+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $5.00 target, Stonegate Capital Blackstone $4. Thompson Reuters rates BPTH as out perform with a target of $3.25. MSCI raised BPTH from 1 to 3.


Zack's rating now equals hold.

                        
 
 
 
SureTrader
Interactive Brokers Advertisement
BPTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#3194   Brettj, SJSTOCKSHARK 10/21/17 01:29:49 PM
#3193   Sad I wasn’t invited to the Chicago meeting. Brettj 10/20/17 10:05:55 PM
#3192   Tribe Public has an impressive website. SJSTOCKSHARK 10/20/17 09:38:02 PM
#3191   Time to get more funding. iloveu2 10/19/17 11:47:34 PM
#3190   Check out these BPTH lunch meetings. I wonder SJSTOCKSHARK 10/19/17 11:56:17 AM
#3189   Blairsoldman, I agree with you but in my Snug9 10/18/17 04:53:36 PM
#3188   Every bit of evidence I can find indicates Brettj 10/18/17 02:20:14 PM
#3187   Thanks Snug. Sounds silly for the FDA blairsoldman 10/18/17 12:57:19 PM
#3186   Blairsoldman, the simple answer to your question is Snug9 10/18/17 12:35:42 PM
#3185   Would someone please clear up a misunderstanding? blairsoldman 10/17/17 10:27:44 PM
#3184   Still waiting for FDA clinical update. SJSTOCKSHARK 10/16/17 10:13:51 AM
#3183   Only gap is the one in your teeth GangstaKitty 10/13/17 04:14:07 PM
#3182   Doen 6.5%!! Wouldn't buy above 0.30. Gap fill Joe Millionaire 10/12/17 05:34:05 PM
#3181   Moffat, I suspect that is a "short" seller SJSTOCKSHARK 10/12/17 02:50:55 PM
#3180   There is 250,000+ for sale at .50. Who dmoffat 10/12/17 01:47:08 PM
#3179   Short interest up 90k. SJSTOCKSHARK 10/12/17 11:00:02 AM
#3178   Thanks me 2 :-) GangstaKitty 10/11/17 05:44:59 PM
#3177   Welcome Gangsta ! Hope you do well here ! too simple 10/11/17 02:19:02 PM
#3176   Took a small position today 10k at .49 GangstaKitty 10/11/17 01:40:17 PM
#3175   Gp, I looked at our prior PPS move SJSTOCKSHARK 10/11/17 11:05:03 AM
#3174   Yep, profit taking and shorts piling on. Gpheart2016 10/11/17 10:41:35 AM
#3173   Today, so far the sucking sound the stock SJSTOCKSHARK 10/11/17 10:35:30 AM
#3172   Brettj, what is that sucking sound we are Snug9 10/10/17 07:30:55 PM
#3171   * * $BPTH Video Chart 10-10-17 * * ClayTrader 10/10/17 04:46:44 PM
#3170   5.5+ million traded and up almost 38%. SJSTOCKSHARK 10/10/17 04:08:59 PM
#3169   That definitely implies something good is happening! But..... dmoffat 10/10/17 03:34:42 PM
#3168   5+ million shares traded and up BIG! SJSTOCKSHARK 10/10/17 03:32:40 PM
#3167   Should we be expecting news at the end dmoffat 10/10/17 12:28:01 PM
#3166   GP, Sorry I meant the "bid" was getting SJSTOCKSHARK 10/10/17 11:11:20 AM
#3165   Once again, I encourage everyone to email Doug Brettj 10/10/17 11:06:57 AM
#3164   Perhaps someone should ask on what date enrollment blairsoldman 10/10/17 11:05:45 AM
#3163   Gp, Almost 900 million shares traded in the SJSTOCKSHARK 10/10/17 10:02:35 AM
#3162   Brettj, I understand the delay in enrolling patients SJSTOCKSHARK 10/10/17 09:54:05 AM
#3161   Last chance to buy under .50? It Gpheart2016 10/10/17 09:53:01 AM
#3160   It was "publicly" announced to our insiders. Pat Torney 10/10/17 09:36:21 AM
#3159   My recent email exchange with Doug with the Brettj 10/10/17 08:50:01 AM
#3158   Unbelievable! The CML combination trial starts without a SJSTOCKSHARK 10/09/17 11:37:19 PM
#3157   I find nothing stating that phase. 2a for Gpheart2016 10/09/17 03:48:12 PM
#3156   So Doug Morris just responded to an email Brettj 10/09/17 01:06:19 PM
#3155   Word, our history is strikingly similar except SJSTOCKSHARK 10/09/17 11:45:10 AM
#3154   That history and legal battle are fascinating. I wordlender 10/09/17 10:02:52 AM
#3153   Word, An update on the ABUS v. Moderna battle: SJSTOCKSHARK 10/06/17 10:40:17 PM
#3152   re:iloveu2 shorting,,,I think you make an excellent point gerry57 10/05/17 06:02:29 PM
#3151   Love, you make a good point and we Gpheart2016 10/05/17 05:38:28 PM
#3150   I don't think PN is a good CEO iloveu2 10/04/17 10:29:42 PM
#3149   Iloveu2, I have been concerned for a long Snug9 10/04/17 07:48:01 PM
#3148   Pat, It makes sense. Thank you. SJSTOCKSHARK 10/04/17 03:45:38 PM
#3147   Patent protection and Orphan Drug Exclusivity (ODE) are Pat Torney 10/04/17 11:26:16 AM
#3146   Pat, What about the "orphan drug" status? Does SJSTOCKSHARK 10/04/17 11:15:39 AM
#3145   Denny, lets be clear that when you say Pat Torney 10/04/17 10:56:50 AM
PostSubject